Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.
Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.
Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.
Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.
The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.
Travere Therapeutics (NASDAQ: TVTX) has announced that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. Investors can access the webcast and dial-in information on Travere's website at ir.travere.com/events-presentations. An archived version of the call will be available for 30 days on the company's website following the live webcast.
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.
Travere Therapeutics (NASDAQ: TVTX) announced on June 11, 2024, that its Compensation Committee granted inducement equity grants to three new employees on June 10, 2024. These grants, consisting of 10,500 inducement restricted stock units (RSUs), are part of the company's efforts to attract new talent. The RSUs are governed by the terms of Travere's 2018 Equity Incentive Plan but were granted outside of this plan as inducements material to the new hires. The RSUs will vest over four years, with 25% vesting each year, contingent upon the employees' continued service with the company.
Travere Therapeutics announced the issuance of inducement equity grants to five new employees under Nasdaq Listing Rule 5635(c)(4) on May 10, 2024.
The grants include stock options for 25,000 shares and restricted stock units (RSUs) for 26,500 shares of common stock. The stock options have an exercise price of $6.30 per share, the closing price on the date of grant, and vest over a four-year period. The RSUs also vest over four years, with 25% of shares vesting annually.
These inducement grants are intended to attract new talent and are issued outside of Travere's 2018 Equity Incentive Plan but adhere to its terms.
Travere Therapeutics, Inc. (Nasdaq: TVTX) will present data on FILSPARI (sparsentan) at the National Kidney Foundation (NKF) Spring Clinical Meetings and the European Renal Association (ERA) Congress. The presentations showcase FILSPARI's efficacy over traditional treatments, highlighting its benefits in patients with IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will be participating in upcoming investor conferences including the BofA Securities Health Care Conference on May 15, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024. The live webcasts of the presentations can be accessed on Travere's website with replays available for 30 days after each event.
Travere Therapeutics reported strong financial results for the first quarter of 2024, showcasing significant growth and achievements in key regulatory milestones. The FDA granted Priority Review for converting FILSPARI to full approval for IgAN in the U.S., with a PDUFA target action date of September 5, 2024. European Commission granted conditional marketing authorization for FILSPARI in Europe. The Company dosed the first patients in the pivotal Phase 3 HARMONY Study and has cash, cash equivalents, and marketable securities totaling $441.0 million as of March 31, 2024.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will report its first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast to discuss the results and provide a business update. Details can be accessed on Travere's Investor page.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
What is the primary focus of Travere Therapeutics?
What is sparsentan?
What recent achievements has Travere Therapeutics made?
What are the indications for FILSPARI®?
Who are Travere Therapeutics' strategic partners?
What is the potential significance of pegtibatinase?
What are the key safety considerations for FILSPARI® therapy?
What is the financial condition of Travere Therapeutics?
How does Travere Therapeutics develop its therapies?
Where can more information about Travere Therapeutics be found?
